골관절염 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 유형별, 해부학적 구조별, 투여 경로별, 판매 채널별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Anatomy, By Route Of Administration, By Sales Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

골관절염 치료제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 골관절염(OA) 치료제 시장 규모는 2030년까지 135억 7,000만 달러에 달할 것으로 예상되며, 2025-2030년 연평균 6.89%의 CAGR을 기록할 것으로 예측됩니다.

골관절염 치료제 시장은 특히 고령화 사회의 OA 환자 증가로 인해 성장세를 보이고 있습니다. 미국에만 3,250만 명 이상의 OA 환자가 있어 효과적인 치료에 대한 수요가 증가하고 있습니다. 현재 진행 중인 연구개발은 새로운 치료법을 창출하는 데 중점을 두고 있으며, 특히 OA라는 질환을 이해하고 그 문제를 해결하기 위한 솔루션을 개발하는 데 중점을 두고 있습니다.

골관절염은 치밀한 조직 구조로 인해 관리가 어렵지만, 관절 내 약물 투여와 같은 새로운 약물의 채택보다 표적 약물전달의 개발이 가속화되고 있습니다. BIO2022에서 OrthoTrophix, Inc.가 무릎 골관절염에 대한 TPX-100의 임상 데이터와 등록 계획을 발표한 것처럼, 시장 관계자들은 시장 확대에 기여할 수 있는 이니셔티브에 주목하고 있습니다.

또한, 특히 질병 변형성 골관절염 치료 연구개발 분야에서는 주요 제약사 및 연구기관들이 많은 노력을 기울이고 있습니다. 예를 들어, 2024년 OARSI 세계 회의에서 발표된 바이오세닉의 3상 데이터는 중증 염증성 무릎 골관절염에 대한 JTA-004의 효능을 보여주었습니다. 사후 분석 결과, JTA-004는 안전하고 효과적이며, 이 특정 아형에 대해 표적 통증 관리를 제공한다는 결론을 내렸습니다. 이러한 약물전달 및 질병 변형 약물의 발전은 학회 발표와 좋은 시험 결과를 통해 입증되고 있으며, 새로운 골관절염 치료제 시장 확대에 기여하고 있습니다.

또한, 비스포스포네이트(항골흡수제)와 Synvisc-ONE 주사제와 같은 개별화 치료의 채택으로 OA 시장은 크게 성장하고 있습니다. 2023년 12월, 컬럼비아대학교 연구진은 관절 연골을 건강하게 유지할 수 있는 성인 생쥐의 줄기세포에 대한 획기적인 발견을 통해 관절 연골을 건강하게 유지할 수 있다는 획기적인 발견을 했습니다. 이 줄기세포의 감소는 노화 및 부상으로 인한 OA 발병의 원인이 되고 있습니다.

이 분야에 투자함으로써 기업은 진화하는 수요에 대응하고 경쟁 우위를 확보할 수 있습니다. 혁신적인 의약품 개발을 주도함으로써 기업은 선두주자로서의 입지를 구축하고 시장에서의 입지를 확고히 할 수 있습니다. 맞춤화된 OA 치료의 등장과 세포 기반 치료법의 발전은 시장 확대의 주요 요인으로, 기업들이 이 분야의 리더로 부상할 수 있는 힘을 제공하고 있습니다.

골관절염 치료제 시장 보고서 하이라이트

• 약물 유형별로는 관절내 대체요법이 2024년 37.06%로 가장 큰 점유율을 차지했으며, OA 증상 관리에 대한 채택과 효과로 인해 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 해부학적 구조별로는 무릎관절염(KOA) 부문이 2024년 42.07%로 압도적인 점유율을 차지했습니다. 무릎 골관절염(KOA)은 전 세계적으로 가장 흔한 만성 관절 질환으로 높은 장애율과 이환율을 특징으로 합니다.
• 투여 경로별로는 비경구 투여가 2024년 압도적인 점유율을 차지했으며, 특정 치료에 대한 효과, 우수한 약동학 및 약력학, 투여 용이성, 높은 예측 성장률로 인해 예측 기간 동안 7.57%의 CAGR로 성장할 것으로 예상됩니다.
• 2024년 골관절염 치료제 시장의 판매 채널별 부문에서는 복합제가 우위를 유지할 것으로 전망됐습니다.
• 최종 용도별로는 병원 약국 부문이 2024년 47.50%로 압도적인 점유율을 차지했습니다.
• 북미 골관절염 치료제 시장은 2024년 37.31%의 점유율을 차지하며 전 세계 시장을 지배했습니다. 북미 시장은 높은 비만 유병률과 정부 지원 정책 등 여러 요인으로 인해 우위를 유지하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 골관절염 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 골관절염 치료제 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석

제4장 골관절염 치료제 시장 : 약물 유형, 추정·동향 분석

• 부문 대시보드
• 약물 유형에 의한 세계의 골관절염 치료제 시장 전망
• 세계의 골관절염 치료제 시장 규모와 동향 분석, 약물 유형별, 2018-2030년
• 관절내 점성보충 제
• 비스테로이드성 항염증제
  • 진통제
  • 코르티코스테로이드
  • 기타

제5장 골관절염 치료제 시장 : 해부학적 구조, 추정·동향 분석

• 부문 대시보드
• 세계의 골관절염 치료제 시장 변동 분석
• 세계의 골관절염 치료제 시장 규모와 동향 분석, 해부학적 구조, 2018-2030년
• 슬관절 골관절염
• 고관절 골관절염
• 손 골관절염
• 기타

제6장 골관절염 치료제 시장 : 투여 경로, 추정·동향 분석

• 부문 대시보드
• 세계의 골관절염 치료제 시장 변동 분석
• 세계의 골관절염 치료제 시장 규모와 동향 분석, 투여 경로별, 2018-2030년
• 비경구 투여
• 국소
• 경구 투여

제7장 골관절염 치료제 시장 : 판매 채널별, 추정·동향 분석

• 부문 대시보드
• 세계의 골관절염 치료제 시장 변동 분석
• 세계의 골관절염 치료제 시장 규모와 동향 분석, 판매 채널별, 2018-2030년
• 배합약
• 시판약

제8장 골관절염 치료제 시장 : 최종 용도별, 추정·동향 분석

• 부문 대시보드
• 세계의 골관절염 치료제 시장 변동 분석
• 세계의 골관절염 치료제 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 병원 약국
• 소매 약국
• 기타

제9장 골관절염 치료제 시장 : 지역별, 추정·동향 분석

• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제10장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점과 채널 파트너 리스트
  • 주요 기업의 시장 점유율 분석, 2024년
  • Sanofi SA
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Bayer AG
  • Zimmer Biomet
  • Novartis AG
  • Anika Therapeutics
  • Assertio Therapeutics, Inc.
  • Bioventus
  • Ferring Pharmaceuticals Inc.

ksm

영문 목차

영문목차

Osteoarthritis Therapeutics Market Growth & Trends:

The global osteoarthritis therapeutics market size is expected to reach USD 13.57 billion by 2030, registering a CAGR of 6.89% from 2025 to 2030, according to a new report by Grand View Research, Inc. The osteoarthritis therapeutics market is on the rise, driven by an increase in OA cases, especially among the aging population. In the U.S. alone, there are over 32.5 million OA patients, highlighting the demand for effective treatments. Ongoing research and development efforts are focused on creating new therapies, with a particular emphasis on understanding the disease and developing solutions to address its challenges.

Managing OA proves difficult owing to its dense tissue structure, but the introduction of novel drugs such as intra-articular drug administration has accelerated the development of targeted drug delivery. Researchers are actively exploring disease-modifying drugs and bioadaptive carriers to enhance the development of innovative osteoarthritis treatments. Market players are taking initiatives to contribute to market expansion, as seen with OrthoTrophix, Inc. presenting clinical data and a registration plan for TPX-100 for knee osteoarthritis at BIO 2022.

In addition, significant efforts are being made by key pharmaceutical companies and research institutes in realm of research and development, especially for disease-modifying osteoarthritis drugs. For instance, BioSenic's Phase 3 data presentation at the 2024 OARSI World Congress showcased the efficacy of JTA-004 in treating severe inflammatory knee osteoarthritis. The post hoc analysis concluded that JTA-004 is both safe and effective, offering targeted pain management for this specific subtype of condition. These advancements in targeted drug delivery and disease-modifying drugs, as demonstrated by presentations and positive trial results, are contributing to the expansion of the market for novel osteoarthritis treatments.

Moreover, the market for OA is experiencing significant growth owing to the introduction of personalized medications such as Bisphosphonates (anti-resorptive drugs) and Synvisc-ONE injection. In addition, pharmaceutical companies and research institutions are actively engaged in developing personalized treatments and cell-based therapies for OA. In December 2023, researchers at Columbia University made a breakthrough discovery of stem cells in adult mice capable of maintaining healthy cartilage in joints, with their decline contributing to OA development due to aging and injury.

Investing in this sector offers companies the opportunity to capitalize on evolving demands, thus gaining a competitive advantage. By leading innovative medication development, companies establish themselves as frontrunners, solidifying their position in the market. The advent of personalized OA medications and advancements in cell-based therapies are key drivers of market expansion, empowering companies to emerge as leaders in the field.

Osteoarthritis Therapeutics Market Report Highlights:

• Based on drug type, the viscosupplementation agents segment accounted for the largest share of 37.06% in 2024 and is expected to grow at the fastest CAGR over the forecast period due to their adoption and efficacy in managing OA symptoms.
• Based on anatomy, the knee osteoarthritis (KOA) segment held a dominant share of 42.07% in 2024. KOA is one of the most common forms of chronic articular disease and OA worldwide and is characterized by high disability & morbidity rates.
• Based on route of administration, the parenteral route segment held a dominant share in 2024 and is expected to grow at a CAGR of 7.57% over the forecast period due to its efficacy for certain therapies, better pharmacokinetics and pharmacodynamics, ease of administration, and higher projected growth rate.
• Prescription drugs are poised to maintain dominance in the osteoarthritis therapeutics market' sales Channel segment in 2024.
• Based on end-use, the hospital pharmacies segment held a dominant share in 2024, accounting for 47.50%.
• North America osteoarthritis therapeutics market dominated the global industry and accounted for a 37.31% share in 2024. The North American market maintains its dominance due to several factors, including a high prevalence of obesity and supportive government policies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Anatomy
  • 1.2.3. Route of Administration
  • 1.2.4. Sales Channel
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug type outlook
  • 2.2.2. Anatomy outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Sales channel outlook
  • 2.2.5. End use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Osteoarthritis Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High Prevalence of Osteoarthritis
    • 3.2.1.2. Growing Aging Population
    • 3.2.1.3. Technological Advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side Effects and Adverse Reactions
    • 3.2.2.2. High cost of osteoarthritis therapeutics drugs
• 3.3. Osteoarthritis Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Osteoarthritis Therapeutics Market: Drug Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Osteoarthritis Therapeutics Market by Drug Type Outlook
• 4.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Viscosupplementation Agents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Nonsteroidal Anti-inflammatory Drugs
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. Naproxen
      • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.2. Aspirin
      • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.3. Diclofenac
      • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.4. Ibuprofen
      • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.5. Celecoxib
      • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.6. Meloxicam
      • 4.5.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.7. Piroxicam
      • 4.5.1.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.8. Ketoprofen
      • 4.5.1.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.9. Other NSAIDs
      • 4.5.1.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Analgesics
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.1. Duloxetine
        • 4.5.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.2. Acetaminophen
        • 4.5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Corticosteroids
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Osteoarthritis Therapeutics Market: Anatomy Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 5.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Anatomy, 2018 to 2030 (USD Million)
• 5.4. Knee Osteoarthritis
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hip Osteoarthritis
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Hand Osteoarthritis
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Osteoarthritis Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 6.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Parenteral Route
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.1. Hyaluronic Acid Injections
      • 6.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2. Corticosteroid Injections
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Platelet-rich Plasma (PRP) Injections
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.4. Placental Tissue Matrix (PTM) Injections
      • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.5. Acetylsalicylic Acid (ASA) Injections
      • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.6. Others
      • 6.4.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Topical Route
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Oral Route
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Osteoarthritis Therapeutics Market: Sales Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 7.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 7.4. Prescription Drugs
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Over-the-Counter Drugs
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Osteoarthritis Therapeutics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 8.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by End Use 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Osteoarthritis Therapeutics Market: Regional Estimates & Trend Analysis by

• 9.1. Regional Market Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2024
  • 10.3.4. Sanofi SA
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. GlaxoSmithKline plc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Pfizer Inc.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bayer AG
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Zimmer Biomet
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Novartis AG
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Anika Therapeutics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Assertio Therapeutics, Inc.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Bioventus
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Ferring Pharmaceuticals Inc.
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives

관련자료